Motilal Oswal has reiterated its BUY rating on Glenmark Pharmaceuticals, setting a compelling price target of Rs 2,430—implying a robust 28% upside from current levels.
Divi's Labs and Glenmark shares jumped to 52-week highs and the stocks closed near their highs. On technical charts, both the stocks are looking strong.